Eli Lilly Ends Coronavirus Antibody Treatment Trial, Other Studies Go On

NPR

27 Oct 2020 0 shares 1 views

Eli Lilly Ends Coronavirus Antibody Treatment Trial, Other Studies Go On

NPR

Published 27 Oct 2020

The trial studied the efficacy of bamlanivimab and remdesivir on hospitalized COVID-19 patients - the same therapies given to President Trump. But researchers say people showed no marked improvement.

Full Article

2nd study testing a COVID-19 antibody drug has a setback

SeattlePI.com 30 Oct 2020

For the second time, a study testing an experimental antibody drug for COVID-19 has been paused to investigate a possible safety..

Eli Lilly wins US$375mln US government order for COVID-19 drug
Proactive Investors 28 Oct 2020
US stocks end mixed session on rising COVID-19 rates and stimulus impasse
Proactive Investors 27 Oct 2020
Wall Street mixed at midday as Nasdaq flies ahead of the Dow
Proactive Investors 27 Oct 2020
Wall Street starts on a mixed note
Proactive Investors 27 Oct 2020

More coverage

Wall Street expected to bounce back from Monday’s slump

Proactive Investors 27 Oct 2020

US indices are expected to claw back some of yesterday’s losses as bargain hunters move back in after yesterday’s..

Lilly antibody drug fails in a COVID-19 study; others go on
SeattlePI.com 27 Oct 2020
Lilly antibody drug fails in a COVID-19 study; others go on
SeattlePI.com 26 Oct 2020
NA Proactive news snapshot: Revive Therapeutics, KULR Technology, Lexaria Bioscience, TRACON Pharmaceuticals UPDATE …
Proactive Investors 26 Oct 2020
NA Proactive news snapshot: BTU Metals, Vuzix Corporation, Bioasis Technologies, Cabral Gold, Klondike Gold UPDATE …
Proactive Investors 20 Oct 2020

Eli Lilly Ends Coronavirus Antibody Treatment Trial, Other Studies Go On

Eli Lilly Ends Coronavirus Antibody Treatment Trial, Other Studies Go On

You might like

Related news coverage

2nd study testing a COVID-19 antibody drug has a setback

Advertisement

More coverage

Wall Street expected to bounce back from Monday’s slump